US drug, biologics chiefs give peek into biosimilar planning efforts
This article was originally published in Scrip
As drug makers anticipate the release of biosimilar guidelines from the US FDA by the end of this year, regulators in a 3 August article in the New England Journal of Medicine (NEJM) gave a peek into some of their expectations for the new approval pathway – an authority the agency gained in last year's health reform bill.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.